

07 May 2021 | **News**

QUOTED. 7 May 2020. Douglas VanOort.

by

Douglas VanOort, the chairman of NeoGenomics, explained the strategic rationale for the company's \$390m purchase of liquid-biopsy company Inivata during NeoGenomic's first quarter 2021 sales and earnings conference call on 5 May.

“Bolstering our comprehensive test menu with the addition of Inivata's leading liquid biopsy technology for detecting circulating tumor DNA will allow NeoGenomics to provide testing solutions to our physicians and their patients for diagnosis, prognosis, therapy selection and now also for post-intervention detection of residual disease and for recurrence monitoring.” – Douglas VanOort, chairman, NeoGenomics

- Find out more: [NeoGenomics Bolsters Liquid Diagnostics Portfolio By Acquiring Inivata](#)

[Click here](#) for a free trial of *Medtech Insight*